You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|
|---|---|
| Published in |
The Lancet, October 2014
|
| DOI | 10.1016/s0140-6736(14)61399-4 |
| Pubmed ID | |
| Authors |
Frederick J Raal, Evan A Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders G Olsson, David Sullivan, G Kees Hovingh, Bertrand Cariou, Ioanna Gouni-Berthold, Ransi Somaratne, Ian Bridges, Rob Scott, Scott M Wasserman, Daniel Gaudet, for the RUTHERFORD-2 Investigators |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 19% |
| Japan | 2 | 13% |
| United States | 2 | 13% |
| Spain | 1 | 6% |
| France | 1 | 6% |
| Turkey | 1 | 6% |
| India | 1 | 6% |
| Unknown | 5 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 44% |
| Practitioners (doctors, other healthcare professionals) | 5 | 31% |
| Scientists | 3 | 19% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 485 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 4 | <1% |
| United States | 3 | <1% |
| Korea, Republic of | 1 | <1% |
| Italy | 1 | <1% |
| Austria | 1 | <1% |
| Germany | 1 | <1% |
| New Zealand | 1 | <1% |
| Brazil | 1 | <1% |
| Spain | 1 | <1% |
| Other | 1 | <1% |
| Unknown | 470 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 62 | 13% |
| Researcher | 61 | 13% |
| Student > Bachelor | 56 | 12% |
| Student > Master | 55 | 11% |
| Student > Ph. D. Student | 50 | 10% |
| Other | 102 | 21% |
| Unknown | 99 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 208 | 43% |
| Pharmacology, Toxicology and Pharmaceutical Science | 38 | 8% |
| Agricultural and Biological Sciences | 27 | 6% |
| Biochemistry, Genetics and Molecular Biology | 25 | 5% |
| Nursing and Health Professions | 11 | 2% |
| Other | 47 | 10% |
| Unknown | 129 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 89. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2023.
All research outputs
#487,909
of 25,837,817 outputs
Outputs from The Lancet
#4,565
of 43,003 outputs
Outputs of similar age
#4,803
of 267,931 outputs
Outputs of similar age from The Lancet
#77
of 536 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 43,003 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 68.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,931 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 536 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.